CORRECTING and REPLACING Phase Forward Customers Automate Adverse Event Reporting Management with Empirica™ Trace

Business Wire, June 23, 2009

Recent Customer Wins Underscore Demand for Company’s Safety Solution

SAN DIEGO -- First graph, second sentence of release, the company name Panacea Pharmaceuticals, Inc. should read Panacea Pharma Projects Limited.

The corrected release reads:

PHASE FORWARD CUSTOMERS AUTOMATE ADVERSE EVENT REPORTING MANAGEMENT WITH EMPIRICA™ TRACE

Recent Customer Wins Underscore Demand for Company’s Safety Solution

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today pointed to a growing list of customers adopting its Empirica™ Trace safety solution over the past year for comprehensive adverse event management. Among others, customers such as Thallion Pharmaceuticals, Panacea Pharma Projects Limited, Bavarian Nordic A/S, Alapis S.A, and the International Institute for the Safety of Medicines Ltd. (ii4sm) are turning to Empirica Trace to efficiently capture and manage spontaneous report data across the full product life cycle, from clinical development through post-marketing.

“We believe that the marked increase in customer pick-up is a clear indicator that our Empirica Trace product is meeting a need across organizations of all sizes and therapeutic areas for a comprehensive safety solution,” said Chan Russell, president, Phase Forward’s Lincoln Safety Group. “These customers tell us that Empirica Trace provides a fundamental building block for efficiently capturing and managing adverse event data.”

The Empirica Suite of Products

The Empirica Suite of products is Phase Forward’s complete solution set for pharmacovigilance and risk management. In addition to the Empirica Trace product, the suite includes Empirica Study (see related release: Phase Forward Introduces Empirica™ Study, Major New Release of Clinical Trials Signal Detection Solution), an award-winning product that provides a dynamic visual data environment for reviewing safety data and detecting signals in trial data, and the Empirica Gateway E2B submission product which offers full support for E2B submission of case reports to regulators, affiliates and partners and receipt of data via E2B standard files. The suite also includes Empirica Signal, a state-of-the-art data mining and signal management product. It provides detection and quantification of safety signals through the use of advanced data mining techniques that can be applied to any spontaneous reporting database.

The Empirica Suite of products, together with the InForm™ Global Trial Management (GTM) eClinical product, the Clarix™ interactive response technology (IRT) for randomization and trial supply management and the recently acquired Waban Software platform for the management of all product safety data, analysis and reports, offers an integrated clinical research system (ICRS) for today’s life science professionals.

Phase Forward will be showcasing its products including Empirica Trace at DIA’s 45th Annual Meeting in San Diego at booth #729.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 290 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Cautionary Statement

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward’s products and services, demand for Phase Forward’s products and services, future business and operations plans of Phase Forward customers, and the ability of Phase Forward’s customers to realize benefits from the use of Phase Forward’s products and services. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward’s customers to realize benefits from the use of its products and services, the possibility that customers’ needs or plans may change over time, the possibility that the level of demand for Phase Forward’s products and services may vary, regulatory changes and competition. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.